Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


New AE linked to AZ vax

Posted 10 June 2021 PM

AstraZeneca's Covid vaccine has hit another hurdle with new research suggesting it may be associated with a small increased risk of a rare bleeding disorder called immune thrombocytopenic purpura (ITP). 

The findings, from a study of 2.53 million adults in Scotland who received their first dose of either the AstraZeneca vaccine or Pfizer's Comirnaty, published in the journal Nature Medicine this week estimates about 11 in every million will develop ITP with the AstraZeneca shot.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options